Rhythm Pharmaceuticals (RYTM) PEG Ratio: History & Chart

Rhythm Pharmaceuticals, Inc.(RYTM)

Biotechnology · Boston, MA

$90.77-1.68 (-1.82%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.

Boston, MA

414 employees

www.rhythmtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: David Meeker

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Rhythm Pharmaceuticals, Inc. (RYTM)	$6.23B	N/A	N/A	N/A	N/A
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.48B	N/A	N/A	N/A	N/A
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.95B	N/A	0.03	0.06	0.06
Lantheus Holdings, Inc. (LNTH)vs ›	$6.51B	N/A	0.53	0.48	0.48
GRAIL Inc. (GRAL)vs ›	$5.89B	N/A	N/A	N/A	N/A
Hims & Hers Health, Inc. (HIMS)vs ›	$6.57B	N/A	N/A	N/A	N/A
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.87B	N/A	N/A	N/A	N/A
Immunovant, Inc. (IMVT)vs ›	$6.63B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.66B	N/A	2.98	2.74	2.10
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.79B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Rhythm Pharmaceuticals, Inc. (RYTM)

$6.23B

N/A

Amneal Pharmaceuticals, Inc. (AMRX)vs ›

$6.48B

N/A

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$5.95B

N/A

0.03

0.06

Lantheus Holdings, Inc. (LNTH)vs ›

$6.51B

N/A

0.53

0.48

GRAIL Inc. (GRAL)vs ›

$5.89B

N/A

Hims & Hers Health, Inc. (HIMS)vs ›

$6.57B

N/A

Kiniksa Pharmaceuticals International, plc (KNSA)vs ›

$5.87B

N/A

Immunovant, Inc. (IMVT)vs ›

$6.63B

N/A

Chemed Corporation (CHE)vs ›

$6.66B

N/A

2.98

2.74

2.10

Iovance Biotherapeutics, Inc. (IOVA)vs ›

$5.79B

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

RYTM PEG Ratio Metrics

RYTM Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics